Coherus is a promising company that did a bad borrowing and has more than paid the price. Its convertible bondholders created a short hedge and have inflicted massive damage on the company's SP.Read more
Coherus Oncology looks like a high-stakes cancer drug story: it has promising programs, but it leans heavily on a small handful of late-stage treatments that still need the right trial results and approvals. Competition, tougher insurance coverage, and slower-than-hoped doctor adoption could keep the business from turning its science into lasting sales.Read more
Coherus Oncology is betting that its cancer drugs can win faster adoption than expected, helped by new treatments and partnerships that could expand its reach beyond the U.S. The catch is it’s still leaning on a small number of key programs, so trial setbacks, rising costs, or tougher competition could quickly change the story.Read more
Key Takeaways Advancement of clinical pipeline and increased physician adoption are expected to drive strong revenue growth and strengthen market position in high-need oncology indications. Strategic global partnerships and operational efficiency initiatives support improved profitability, lower financial risk, and long-term sustainable earnings expansion.Read more
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
